Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, today announced that it has signed a lease for 18,000 square feet of lab space at 65 Grove Street in the emerging biotech hotbed of Watertown, Mass. Read more >>
Platelet BioGenesis (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, announced today the hiring of Sam Rasty, Ph.D., as President and CEO. Read more >>
Another summer starts with a bang for Boston startups, which raised over $500 million in June. Read more >>
Platelet BioGenesis, the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, announced today the addition of Dr. Richard Murray, president and CEO of Jounce Therapeutics, to its board of directors. Read more >>
The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant concern – an inadequate supply of platelets at blood centers across the country. Read more >>
Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, and Scaled Biolabs (Scaled) announced the two firms are collaborating to optimize PBG’s unique production process for making human platelets, or PLTs+™. The agreement was announced at the SynBioBeta 2018 biology summit. Read more >>
Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, announced it has moved into brand new lab space in Cambridge, MA. Located next to MIT, the newly renovated property puts Platelet BioGenesis in the heart of the most dynamic biotech cluster in the world. Read more >>
Cambridge, Massachusetts-based Platelet Biogenesis was awarded a two-year, $3.5 million grant from the U.S. Department of Defense. The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets. Read more >>
Platelet BioGenesis, the leader in the production of functional human platelets (PLTs+TM) from stem cells and the development of platelet-based therapeutics, announced it has recruited a team of world-renowned experts to its newly formed scientific advisory board. Read more >>
Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>
